Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus.
Fiche publication
Date publication
décembre 2020
Journal
World journal of hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BARDOU Marc, Pr DI MARTINO Vincent
Tous les auteurs :
Brayette A, Essig M, Carrier P, Debette-Gratien M, Labrunie A, Alain S, Maynard M, Ganne-Carrié N, Nguyen-Khac E, Pinet P, De Ledinghen V, Renou C, Mathurin P, Vanlemmens C, Di Martino V, Gervais A, Foucher J, Isabelle FH, Vergniol J, Hourmand-Ollivier I, Cohen D, Duval X, Poynard T, Bardou M, Abergel A, Dao MT, Thévenot T, Hiriart JB, Canva V, Lassailly G, Aurières C, Boyer N, Thabut D, Bernard PH, Schnee M, Larrey D, Hanslik B, Hommel S, Jacques J, Loustaud-Ratti V
Lien Pubmed
Résumé
The recommended monitoring tools for evaluating nucleot(s)ide analogue renal toxicity, such as estimated glomerular filtration rate (eGFR) and phosphatemia, are late markers of proximal tubulopathy. Multiple early markers are available, but no consensus exists on their use.
Mots clés
Biomarkers, Hepatitis B virus, Nucleoside analogues, Proximal tubulopathy, Renal insufficiency
Référence
World J Hepatol. 2020 Dec 27;12(12):1326-1340